Cancer is an acquired disease in which it is possible to identify a va
riety of abnormalities at a genetic level. This holds a promise that g
enetic manipulation of tumour cells will lead to novel therapies. As y
et these approaches are constrained by available methods for obtaining
gene transfer and subsequent genetic control. However, a number of st
rategies are already reaching the clinic, including attempts at immuno
therapy, prodrug activation and improving host defence against convent
ional chemotherapy. Further clinical opportunities will occur with imp
roved vector development.